52
Participants
Start Date
October 2, 2018
Primary Completion Date
December 13, 2019
Study Completion Date
December 13, 2019
JNJ-53718678, 2000 mg
Participants will be administered JNJ-53718678, 2000 mg as oral suspension in Part 1 (Panel 1).
JNJ-53718678, 3000 mg
Participants will be administered JNJ- 53718678, 3000 mg as oral suspension in Part 1 (Panel 2).
JNJ-53718678, 4500 mg or Dose to be decided
Participants will be administered JNJ-53718678, 4500 mg as oral suspension in Part 1 (Panel 3). If this dose is considered safe and tolerable and if pharmacokinetic data require further dose escalation, then participants will receive JNJ-53718678 (Dose to be decided) in Part 1 (Panel 4). This dose (either from Panel 3 or Panel 4 ) will be used in Part 2 (Dose may be lower/higher based on review of safety, tolerability, and PK data obtained in Part 1).
JNJ-53718678 500 mg
Participants will be administered JNJ-53718678, 500 mg as oral suspension in Part 2.
JNJ-53718678 Placebo
Participants will be administered JNJ-53718678 matching placebo in Part 1 and 2.
Moxifloxacin 400 mg
Participants will be administered moxifloxacin 400 mg as capsule in Part 2.
Moxifloxacin Placebo
Participants will be administered moxifloxacin matching placebo in Part 2.
Clinical Pharmacology Unit, Merksem
Janssen Research & Development, LLC
INDUSTRY